The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

Background: MDM2 acts as a principal regulator of the tumour suppressor p53 by targeting its destruction through the ubiquitin pathway. A polymorphism in the MDM2 promoter (SNP309) was recently identified. SNP309 was shown to result, via Sp1, in higher levels of MDM2 RNA and protein, and subsequent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Alhopuro, P, Ylisaukko-oja, S, Koskinen, W, Bono, P, Arola, J, Jarvinen, H, Mecklin, J, Atula, T, Kontio, R, Makitie, A, Suominen, S, Leivo, I, Vahteristo, P, Aaltonen, L
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2005
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1736129/
https://ncbi.nlm.nih.gov/pubmed/16141004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmg.2005.031260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars